[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019009759A - Composiciones de peptido estables. - Google Patents

Composiciones de peptido estables.

Info

Publication number
MX2019009759A
MX2019009759A MX2019009759A MX2019009759A MX2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A
Authority
MX
Mexico
Prior art keywords
peptide compositions
stable peptide
stable
kits
buffering
Prior art date
Application number
MX2019009759A
Other languages
English (en)
Inventor
Gordon W Laurie
Marc G Odrich
Michelle Carpenter
Thomas R Gadek
Paul A Laskar
Original Assignee
Tearsolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tearsolutions Inc filed Critical Tearsolutions Inc
Publication of MX2019009759A publication Critical patent/MX2019009759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Esta solicitud se refiere generalmente a composiciones de péptido estables y kits que comprenden bajos niveles de agentes reguladores y quelantes, y métodos para utilizar las mismas.
MX2019009759A 2017-02-21 2018-02-20 Composiciones de peptido estables. MX2019009759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461467P 2017-02-21 2017-02-21
US201762530565P 2017-07-10 2017-07-10
PCT/US2018/018775 WO2018156501A1 (en) 2017-02-21 2018-02-20 Stable peptide compositions

Publications (1)

Publication Number Publication Date
MX2019009759A true MX2019009759A (es) 2020-07-27

Family

ID=63252954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009759A MX2019009759A (es) 2017-02-21 2018-02-20 Composiciones de peptido estables.

Country Status (11)

Country Link
US (2) US20190381136A1 (es)
EP (1) EP3585412A4 (es)
JP (2) JP7223712B2 (es)
KR (1) KR20190137788A (es)
CN (1) CN110461350B (es)
AU (3) AU2018225485B2 (es)
BR (1) BR112019017275A2 (es)
CA (1) CA3054290A1 (es)
MX (1) MX2019009759A (es)
RU (1) RU2019126279A (es)
WO (1) WO2018156501A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3986914A4 (en) * 2019-06-19 2023-07-19 TearSolutions, Inc. RESTRAINED PEPTIDES
WO2021022045A1 (en) 2019-07-31 2021-02-04 Ecolab Usa Inc. Personal protective equipment free delimer compositions
CN113209273B (zh) * 2021-04-30 2024-06-07 江苏普莱医药生物技术有限公司 一种抗菌肽涂剂及其制备方法
WO2024006653A2 (en) * 2022-07-01 2024-01-04 Tearsolutions, Inc. Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027205A2 (en) 1996-12-18 1998-06-25 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AUPO500997A0 (en) 1997-02-07 1997-03-06 Macquarie Research Limited Diagnosis of disease using tears
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
ES2330087T3 (es) 2001-02-20 2009-12-04 University Of Virginia Patent Foundation Proteina analoga al factor de crecimiento de las lagrimas oculares.
CN1700894A (zh) 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
CA2566607C (en) 2004-05-13 2014-04-15 University Of Virginia Patent Foundation Use of lacritin in promoting ocular cell survival
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
WO2006049250A1 (ja) * 2004-11-05 2006-05-11 Senju Pharmaceutical Co., Ltd. 眼内移行性促進水性点眼剤
EP1906986A4 (en) * 2005-06-17 2011-02-23 Regenerx Biopharmaceuticals LKKTET AND / OR LKKTNT PEPTIDE COMPOSITIONS LYOPHILIZED OR PROVIDED IN A LYOPHILIC FORM
US7932227B1 (en) 2007-09-17 2011-04-26 University Of Virginia Patent Foundation Lacritin-syndecan fusion proteins
EP2270141B9 (en) * 2008-03-19 2015-12-16 Senju Pharmaceutical Co., Ltd. Partial peptide of lacritin
JP2012528888A (ja) * 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド 眼科用配合剤、その製造方法およびその使用方法
JP5716018B2 (ja) 2009-09-16 2015-05-13 千寿製薬株式会社 ラクリチンの部分ペプチド
CN103501804A (zh) * 2010-12-21 2014-01-08 雷科制药公司 眼泪替代物
AU2015229452B2 (en) 2014-03-12 2021-07-15 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease

Also Published As

Publication number Publication date
CN110461350B (zh) 2024-09-24
AU2021221401B2 (en) 2023-11-09
JP7223712B2 (ja) 2023-02-16
JP2023058566A (ja) 2023-04-25
AU2024200748A1 (en) 2024-02-29
WO2018156501A1 (en) 2018-08-30
KR20190137788A (ko) 2019-12-11
CA3054290A1 (en) 2018-08-30
AU2021221401A1 (en) 2021-09-09
US12064469B2 (en) 2024-08-20
CN110461350A (zh) 2019-11-15
RU2019126279A3 (es) 2021-06-02
US20190381136A1 (en) 2019-12-19
US20220305083A1 (en) 2022-09-29
BR112019017275A2 (pt) 2020-05-12
AU2018225485A1 (en) 2019-09-05
EP3585412A4 (en) 2020-12-09
EP3585412A1 (en) 2020-01-01
JP2020508349A (ja) 2020-03-19
RU2019126279A (ru) 2021-03-23
AU2018225485B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
ZA201906822B (en) Indole ahr inhibitors and uses thereof
PH12019502279A1 (en) Cleaning compositions and uses thereof
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2019011496A (es) Composiciones de niraparib.
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
WO2019020602A3 (en) LUMINOPHORE AND COMPOSITION
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
ZA202309446B (en) Rapamycin analogs and uses thereof
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX2020001885A (es) Formulaciones de daptomicina.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2019009759A (es) Composiciones de peptido estables.